Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 69
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Spinal Cord ; 57(5): 388-395, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30626977

RESUMEN

STUDY DESIGN: Retrospective cohort study. OBJECTIVES: To assess the effectiveness and complications of treatment for neurogenic stress urinary incontinence (nSUI) by Adjustable Continence Therapy (ACT™ and ProACT™). SETTING: France. METHODS: A retrospective multicentre study of consecutive patients with neurological pathologies treated for nSUI with ACT balloons. RESULTS: From January 2001 to January 2013, 102 patients were implanted. Mean (SD) age at implantation was 48.4 (16.5) years. Patients were followed-up for a mean 2.7 (2.3) years. After implantation, 5.9% of patients were totally continent, 51.2% had an improvement in symptoms of at least 50% (including 14.6% with improvements of at least 90%), and 48.8% had improvements of < 50%, including 7.3% of treatment failures. Complications occurred in 70 patients (120 balloons): 21 balloon infections, 34 migrations, 18 device failures, 28 urethral erosions and 28 cutaneous erosions. The procedure was ineffective for 35 patients. Twenty patients underwent permanent explantation. The rate of migrations was lower in patients with upper motor neuron lesion than in those with lower motor neuron lesion (p = 0.04). CONCLUSIONS: ACT is a minimally invasive treatment for SUI related to sphincter deficiency. This is one of the first reports in a sample of patients with neurological disorders implanted by multiple surgeons. ACT could be a less invasive, appropriate alternative to artificial urinary sphincters. However, it is associated with frequent local complications which are easy to manage but that should be reduced in this challenging population.


Asunto(s)
Vejiga Urinaria Neurogénica/diagnóstico , Vejiga Urinaria Neurogénica/terapia , Incontinencia Urinaria de Esfuerzo/diagnóstico , Incontinencia Urinaria de Esfuerzo/terapia , Urodinámica/fisiología , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Cabestrillo Suburetral , Adulto Joven
2.
Neurourol Urodyn ; 37(8): 2758-2762, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30203509

RESUMEN

AIMS: To evaluate the impact of the pre-operative maximum detrusor pressure (MDP) on efficacy outcomes after incontinentation by sphincterotomy or urethral stent placement in male patients with neurogenic detrusor-sphincter dyssynergia (DSD). METHODS: A retrospective study was performed in 41 male patients treated between 2006 and 2013 in a tertiary reference center. All patients had a neurogenic DSD confirmed by baseline urodynamic studies, and were unable or secondary failed to practice CISC. Success was defined as a post-void residual volume <150 mL. Influence of MDP on treatment efficacy was evaluated through a Mann-Whitney U-Test. RESULTS: Median (range) age was 39 years (20-69). Spinal cord injury was the main underlying condition. Twenty-six patients had a sphincteric stent placement (Memocath®, Bard, Covington) and 15 had surgical sphincterotomy. Treatment was successful in 31 patients (76%). Patients with immediate successful outcomes had a significantly higher mean preoperative MDP (59.6 vs 29.7 cmH2 O; P = 0.002). Patients with MDP over the threshold of 40 cmH2 O had a 90% success rate. These differences were maintained at 6 months, MDP being higher in the success group than in the failure group (59.5 vs 39.8 cmH2 O, respectively, P = 0.008). The technique used (stent placement or incision) had no impact on immediate or 6-month success rates. CONCLUSIONS: Our results suggested that MDP is associated with treatment success rate after surgical management of DSD of neurogenic origin by sphincteric stent placement or surgical sphincterotomy. A threshold of 40 mH2 O is associated with higher success rates.


Asunto(s)
Uretra/fisiopatología , Uretra/cirugía , Vejiga Urinaria Neurogénica/fisiopatología , Vejiga Urinaria Neurogénica/cirugía , Vejiga Urinaria/fisiopatología , Adulto , Anciano , Humanos , Masculino , Persona de Mediana Edad , Cuidados Preoperatorios , Implantación de Prótesis , Estudios Retrospectivos , Esfinterotomía/métodos , Traumatismos de la Médula Espinal/complicaciones , Stents , Resultado del Tratamiento , Vejiga Urinaria Neurogénica/etiología , Incontinencia Urinaria/etiología , Incontinencia Urinaria/fisiopatología , Incontinencia Urinaria/cirugía , Urodinámica , Procedimientos Quirúrgicos Urológicos/métodos , Adulto Joven
3.
J Urol ; 196(3): 809-18, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27063854

RESUMEN

PURPOSE: We investigated improvements in overactive bladder and patient reported outcomes in patients with overactive bladder and refractory incontinence treated with mirabegron 50 mg plus solifenacin 5 mg vs solifenacin 5 or 10 mg. MATERIALS AND METHODS: Patients with overactive bladder who were incontinent despite 4 weeks of single-blind daily solifenacin 5 mg were randomized 1:1:1 to a double-blind daily combination of mirabegron 50 mg/solifenacin 5 mg, or solifenacin 5 or 10 mg for 12 weeks. The mirabegron dose was increased from 25 to 50 mg after week 4. Symptom bother, health related quality of life and patient perception of bladder condition were assessed by OAB-q (Overactive Bladder Questionnaire) and the PPBC (Patient Perception of Bladder Condition) questionnaire, respectively. Responder rates were based on a 50% reduction in daily incontinence, zero incontinence episodes and fewer than 8 micturitions per 24 hours with minimal important differences in OAB-q and PPBC. RESULTS: Overall 2,174 patients with a median age of 59 years were randomized, including 727 to the combination, 728 to solifenacin 5 mg and 719 to solifenacin 10 mg. Symptom bother, total health related quality of life and its subscales (coping, concern and social), and PPBC were significantly improved with combination vs solifenacin monotherapy (p <0.05). The odds of achieving clinically meaningful improvements in incontinence, micturition frequency, symptom bother, health related quality of life and PPBC were significantly higher for combination than solifenacin monotherapy. The odds of becoming continent was 47% and 28% higher for combination vs solifenacin 5 and 10 mg (OR 1.47, 95% CI 1.17-1.84, p = 0.001 and OR 1.28; 95% CI 1.02-1.61, p = 0.033, respectively). CONCLUSIONS: Significantly more patients on the combination achieved clinically meaningful improvements in incontinence and micturition frequency. Improvements were accompanied by similar improvements in PPBC, symptom bother and health related quality of life.


Asunto(s)
Acetanilidas/administración & dosificación , Succinato de Solifenacina/administración & dosificación , Tiazoles/administración & dosificación , Vejiga Urinaria Hiperactiva/tratamiento farmacológico , Incontinencia Urinaria/tratamiento farmacológico , Urodinámica/efectos de los fármacos , Adolescente , Agonistas de Receptores Adrenérgicos beta 3/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Antagonistas Muscarínicos/administración & dosificación , Calidad de Vida , Factores de Tiempo , Resultado del Tratamiento , Vejiga Urinaria Hiperactiva/complicaciones , Vejiga Urinaria Hiperactiva/fisiopatología , Incontinencia Urinaria/complicaciones , Incontinencia Urinaria/fisiopatología , Adulto Joven
4.
Curr Opin Urol ; 26(1): 17-21, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26574877

RESUMEN

PURPOSE OF REVIEW: Lower urinary tract symptoms (LUTS) in men are highly prevalent, and include both storage and voiding symptoms in many cases. The effect of benign prostatic obstruction (BPO) relief on storage symptoms remains unclear. RECENT FINDINGS: The present review summarizes data about the relation between overactive bladder (OAB), voiding symptoms, and urodynamic characteristics in men with LUTS. Pathomechanisms of OAB in a context of BPO are reviewed. Rates of persistent bladder dysfunction after BPO relief are described along with predictive factors of persisting OAB. SUMMARY: OAB is a common clinical feature in a population of male LUTS, often concomitant with voiding symptoms. Although detrusor overactivity is found in some patients with OAB and BPO, there is no absolute correspondence between clinical symptoms and urodynamic findings. In the context of BPO, OAB pathophysiology implicates nitric oxide pathway, bladder ischemia, ageing of the urinary tract, and calcium-activated potassium channels activity. BPO relief can be followed in the medium term by persistence of OAB symptoms, and preoperative detrusor overactivity has been identified as the main predictive factor. However, preoperative urodynamics remain only indicated in specific cases, when it could directly influence clinical decision-making. Antimuscarinics may be the treatment of choice for persistent symptoms after surgery, but there is no firm recommendation in this clinical setting.


Asunto(s)
Síntomas del Sistema Urinario Inferior/cirugía , Prostatectomía , Hiperplasia Prostática/cirugía , Vejiga Urinaria Hiperactiva/cirugía , Vejiga Urinaria/fisiopatología , Humanos , Síntomas del Sistema Urinario Inferior/diagnóstico , Síntomas del Sistema Urinario Inferior/etiología , Síntomas del Sistema Urinario Inferior/fisiopatología , Masculino , Antagonistas Muscarínicos/uso terapéutico , Hiperplasia Prostática/complicaciones , Hiperplasia Prostática/diagnóstico , Hiperplasia Prostática/fisiopatología , Recuperación de la Función , Factores de Riesgo , Factores Sexuales , Resultado del Tratamiento , Vejiga Urinaria/efectos de los fármacos , Vejiga Urinaria Hiperactiva/diagnóstico , Vejiga Urinaria Hiperactiva/etiología , Vejiga Urinaria Hiperactiva/fisiopatología , Urodinámica , Agentes Urológicos/uso terapéutico
5.
Int Braz J Urol ; 42(3): 494-500, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27286112

RESUMEN

PURPOSE: to assess the efficacy of transcorporal artificial urinary sphincter (AUS) implantation on continence for male stress urinary incontinence in cases of prior surgical treatment or/and radiation failure, and as a first option in radiation patients. MATERIALS AND METHODS: From March 2007 to August 2012, 37 male patients were treated with transcorporal AUS AMS™ 800. Twelve patients had primary placement of transcorporal cuff, a surgical option due to a previous history of radiation and 25 patients had secondary procedure after failure of AUS or urinary incontinence surgery. Functional urinary outcomes were assessed by daily pad use, 24-hour Pad-test and ICIQ-SF questionnaire. Quality of life and satisfaction were assessed based on I-QoL and PGI-I questionnaires. RESULTS: After a median of 32 months, the continence rate (0 to 1 pad) was 69.7%. Median pad test was 17.5g (0-159), mean ICIQ-SF score was 7.3/21 (±5.4) and mean I-QoL score was 93.9/110. A total of 88% of the patients reported satisfaction with the AUS. The 5-year actuarial revision-free for AUS total device was 51%. Patients for primary implant for radiation were not more likely to experience revision than non-radiation patients. Preservation of erections was reported in half of the potent patients. CONCLUSIONS: Transcorporal AUS cuff placement is a useful alternative procedure option for severe male UI treatment, especially in patients with a compromised urethra after prior surgery or radiation. A high continence rate was reported and implantation as first option in radiation patients should be considered.


Asunto(s)
Uretra/efectos de la radiación , Uretra/cirugía , Incontinencia Urinaria de Esfuerzo/cirugía , Esfínter Urinario Artificial , Anciano , Supervivencia sin Enfermedad , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Erección Peniana , Complicaciones Posoperatorias , Prostatectomía/efectos adversos , Calidad de Vida , Reproducibilidad de los Resultados , Estudios Retrospectivos , Estadísticas no Paramétricas , Encuestas y Cuestionarios , Factores de Tiempo , Resultado del Tratamiento , Incontinencia Urinaria de Esfuerzo/etiología , Incontinencia Urinaria de Esfuerzo/radioterapia
6.
World J Urol ; 33(8): 1103-7, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25208805

RESUMEN

PURPOSE: To evaluate the safety and efficacy of retroperitoneal laparoscopic resection in patients with pheochromocytoma in a retrospective study. METHODS: Clinical data of patients with adrenal and extra-adrenal pheochromocytomas, operated on between September 1998 and September 2008 at two institutions, including information on patient demographics, surgical procedure, complications and hospital stay were retrieved. RESULTS: Seventy-two retroperitoneal laparoscopic resections were performed (68 patients, 30 males/38 females). Mean age was 51.4 years (15-87 years). Four patients had a bilateral pheochromocytoma. Median BMI was 27 kg/m(2) (interquartile range 23-29). Mean tumour diameter was 4.6 cm (1.3-9). Thirteen patients had a tumour >6 cm. Mean operation time was 110 min (40-210), and median blood loss during surgery was 160 ml (0-1200 ml). Duration of surgery significantly increased with BMI (p = 0.004) and tumour size (p = 0.004). Four patients required conversion to open surgery (two bleeding, one severe adhesion to inferior vena cava and one renal artery aneurysm). Five patients required a blood transfusion with minor postoperative complications in three patients. Major perioperative haemodynamic variations (systolic blood pressure > 180 mmHg, diastolic blood pressure < 70 mmHg) were observed in 54 % of patients, 30 % required postoperative adrenergic drug treatment. The only predictive factor of a perioperative haemodynamic complication was the high level of normetanephrine in the preoperative blood samples. The median postoperative hospital stay was 4.5 days. Blood loss, postoperative complication and postoperative hospital stay did not increase in patients with tumours >6 cm. CONCLUSION: Retroperitoneal laparoscopic surgery for pheochromocytoma is reproducible, safe and effective.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales/cirugía , Adrenalectomía/métodos , Laparoscopía/métodos , Feocromocitoma/cirugía , Neoplasias Retroperitoneales/cirugía , Adolescente , Neoplasias de las Glándulas Suprarrenales/patología , Adulto , Anciano , Anciano de 80 o más Años , Pérdida de Sangre Quirúrgica , Índice de Masa Corporal , Estudios de Cohortes , Conversión a Cirugía Abierta/estadística & datos numéricos , Femenino , Humanos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Feocromocitoma/patología , Complicaciones Posoperatorias , Neoplasias Retroperitoneales/patología , Espacio Retroperitoneal/cirugía , Estudios Retrospectivos , Resultado del Tratamiento , Carga Tumoral , Adulto Joven
7.
Int Braz J Urol ; 40(6): 828-34, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25615252

RESUMEN

INTRODUCTION AND HYPOTHESIS: To our knowledge a study regarding the efficacy of Pelvisoft® Biomesh for cystocele repair has not previously been reported in the literature. The aim of our study was to assess the long-term efficacy, subjective outcomes and complications in the use of a non-synthetic porcine skin mesh graft (Pelvisoft® Biomesh) associated with transvaginal anterior colporrhaphy in the treatment of cystocele prolapse. MATERIALS AND METHODS: A retrospective study was performed at a single centre. Thirty-three women aged 35-77 years underwent cystocele repair using Pelvisoft® graft between December 2005 and June 2009. Twenty-nine women who underwent transvaginal cystocele repair with Pelvisoft® Biomesh for over a 2 years period were assessed. Four patients were lost to follow-up. Cystocele repair was performed via the vaginal route using Pelvisoft® Biomesh implant by inserting it in the anterior vaginal wall. RESULTS: The median follow-up time was 54.0 months. The rate of recurrence was 17.3%. A total of 6.9% of patients presented early mesh exposure treated by conservative treatment. The mean PFDI-20 score was 72.2. Among sexually active women, the mean PISQ 12 was 33.9 but 56.2% had dyspareunia. After surgery, 6 patients had de novo intercourse. CONCLUSIONS: Our results show that the use of Pelvisoft® biomaterial associated with anterior colporrhaphy for cystocele repair appears to be safe with acceptable failure and complication rates at long term. Nevertheless, an adverse impact on sexual function was reported by the majority of patients.


Asunto(s)
Materiales Biocompatibles/uso terapéutico , Cistocele/cirugía , Mallas Quirúrgicas , Vagina/cirugía , Adulto , Anciano , Animales , Materiales Biocompatibles/efectos adversos , Femenino , Humanos , Ilustración Médica , Persona de Mediana Edad , Periodo Posoperatorio , Recurrencia , Estudios Retrospectivos , Estadísticas no Paramétricas , Mallas Quirúrgicas/efectos adversos , Porcinos , Resultado del Tratamiento , Incontinencia Urinaria de Esfuerzo/cirugía
8.
Rev Infirm ; (179): 42-4, 2012 Mar.
Artículo en Francés | MEDLINE | ID: mdl-22506376

RESUMEN

Two expert nurses can now carry out urodynamic testing in accordance with a protocol of cooperation between health professionals signed last November. The urology department of Rouen University Hospital is thereby validating two years of work and is fully in line with the framework of the hospital, patients, health and territories law. An account of a process which serves as a model.


Asunto(s)
Conducta Cooperativa , Relaciones Interprofesionales , Personal de Enfermería en Hospital , Urodinámica , Francia , Humanos
9.
Ann Surg ; 253(4): 720-32, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21475012

RESUMEN

BACKGROUND: Sacral nerve modulation (SNM) is an established treatment for urinary and fecal incontinence in patients for whom conservative management has failed. OBJECTIVE: This study assessed the outcome and cost analysis of SNM compared to alternative medical and surgical treatments. METHODS: Clinical outcome and cost-effectiveness analyses were performed in parallel with a prospective, multicenter cohort study that included 369 consecutive patients with urge urinary and/or fecal incontinence. The duration of follow-up was 24 months, and costs were estimated from the national health perspective. Cost-effectiveness outcomes were expressed as incremental costs per 50% of improved severity scores (incremental cost-effectiveness ratio). RESULTS: The SNM significantly improved the continence status (P < 0.005) and quality of life (P < 0.05) of patients with urge urinary and/or fecal incontinence compared to alternative treatments. The average cost of SNM for urge urinary incontinence was ∈8525 (95% confidence interval, ∈6686-∈10,364; P = 0.001) more for the first 2 years compared to alternative treatments. The corresponding increase in cost for subjects with fecal incontinence was ∈6581 (95% confidence interval, ∈2077-∈11,084; P = 0.006). When an improvement of more than 50% in the continence severity score was used as the unit of effectiveness, the incremental cost-effectiveness ratio for SNM was ∈94,204 and ∈185,160 at 24 months of follow-up for urinary and fecal incontinence, respectively. CONCLUSIONS: The SNM is a cost-effective treatment for urge urinary and/or fecal incontinence.


Asunto(s)
Terapia por Estimulación Eléctrica/economía , Incontinencia Fecal/terapia , Costos de la Atención en Salud , Plexo Lumbosacro , Incontinencia Urinaria/terapia , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Análisis Costo-Beneficio , Terapia por Estimulación Eléctrica/métodos , Electrodos Implantados , Incontinencia Fecal/diagnóstico , Incontinencia Fecal/economía , Femenino , Estudios de Seguimiento , Francia , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Calidad de Vida , Medición de Riesgo , Estadísticas no Paramétricas , Resultado del Tratamiento , Incontinencia Urinaria/diagnóstico , Incontinencia Urinaria/economía , Adulto Joven
10.
J Urol ; 184(6): 2389-94, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20952009

RESUMEN

PURPOSE: We evaluated quality of life in adults with bladder exstrophy-epispadias complex to improve patient and parent counseling. MATERIALS AND METHODS: We evaluated quality of life in a multicenter study using the SF-36® Medical Outcome Study questionnaire and a local questionnaire. A total of 47 patients born in 1957 to 1990 were followed due to bladder exstrophy-epispadias complex at the 4 participating hospitals. RESULTS: Nine women and 16 men were included in analysis, including 15 who underwent staged reconstruction for bladder exstrophy-epispadias complex and 10 who underwent primary or secondary urinary diversion. Nine patients were married and 2 were in a long-term partnership. A total of 22 patients achieved a high school degree with examination success and 17 worked full time. Six women and 12 men achieved penetrative intercourse. A total of 13 children were born to 3 women and 7 men. Quality of life scores in our patients were less than the norm based scores on 2 of the 8 health concepts, including limitations in physical activity due to health problems and general health perception. Results were statistically different among patients depending on dryness, voiding and urinary reconstruction/diversion. Patient scores did not differ in regard to gender, number of interventions, sexual life, cosmesis or renal function. CONCLUSIONS: Patient scores were less than norm based scores on only 2 health concepts and patients were generally well integrated into society. Urinary diversion was usually well tolerated. It remains a therapeutic option when incontinence interferes with social life or renal function is compromised.


Asunto(s)
Anomalías Múltiples , Extrofia de la Vejiga , Epispadias , Calidad de Vida , Anomalías Múltiples/diagnóstico , Adulto , Extrofia de la Vejiga/complicaciones , Extrofia de la Vejiga/diagnóstico , Epispadias/complicaciones , Epispadias/diagnóstico , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Encuestas y Cuestionarios , Factores de Tiempo , Adulto Joven
11.
Neurourol Urodyn ; 29(1): 179-90, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20025026

RESUMEN

AIMS: The committee was charged with the responsibility of reviewing and evaluating all published data relating to surgical treatment of male urinary incontinence since the previous consultation in 2004. METHODS: Articles from peer-reviewed journals, abstracts from scientific meetings, and literature searches by hand and electronically formed the basis of this review. The articles were evaluated using Levels of Evidences adapted by the ICUD from the Oxford Centre for Evidence Based Medicine. The Recommendations for Care were based on the level of evidence and discussed among the committee members to reach consensus. The incontinence problems were classified according to their etiology, that is, either primarily sphincter or bladder related. RESULTS: Specialist evaluation of the patient is primarily a clinical approach with history, frequency-volume chart, physical examination, and post-void residual urine. Other investigations such as radiographic imaging of the lower urinary tract, cystoscopy, and urodynamic studies can provide important information for the clinician. For stress incontinence of various etiologies the artificial urinary sphincter (AUS) has the longest record of satisfactory results. Consideration must be given to the need for revisions for mechanical breakdown, erosion/infection, and recurrent incontinence, as well as cost. Sling procedures are increasingly being reported to have good outcomes for mild to moderate incontinence. Injectable agents have not shown durable results but newer technologies such as volume-adjustable balloons have shown favorable early results. Incontinence following cystectomy with neobladder and pelvic trauma has been treated most commonly with the AUS. CONCLUSIONS: Although the literature is replete with well-done cohort studies, there is a need for prospective randomized clinical trials. Recommendations for trials include standardized workup and outcome measures and complete reporting of adverse events and long-term results. Further research is also needed to elucidate the mechanism of post-prostatectomy incontinence.


Asunto(s)
Salud del Hombre , Incontinencia Urinaria de Esfuerzo/cirugía , Procedimientos Quirúrgicos Urológicos Masculinos/normas , Investigación Biomédica/normas , Cistectomía/efectos adversos , Medicina Basada en la Evidencia , Humanos , Masculino , Prostatectomía/efectos adversos , Radioterapia/efectos adversos , Factores de Riesgo , Estructuras Creadas Quirúrgicamente/efectos adversos , Resultado del Tratamiento , Uretra/lesiones , Incontinencia Urinaria de Esfuerzo/diagnóstico , Incontinencia Urinaria de Esfuerzo/etiología , Incontinencia Urinaria de Esfuerzo/fisiopatología , Urodinámica , Procedimientos Quirúrgicos Urológicos Masculinos/efectos adversos
12.
Int Braz J Urol ; 35(6): 706-13; discussion 714-5, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-20028576

RESUMEN

PURPOSE: Post-prostatectomy incontinence remains a problem, even in minor or moderate degrees. In order to minimize surgical morbidity and costs, sling procedures have been proposed. The authors have developed a new transobturator male sling procedure and report their results after one-year experience. MATERIALS AND METHODS: A prospective multicenter study was conducted in 50 patients with minor or moderate post-prostatectomy incontinence. Evaluation of TOMS two arms bulbar sling was based on clinical form assessment, The International Consultation on Incontinence Questionnaire (ICIQ) and short-form (SF) 36 questionnaire pre and postoperatively and at 3, 6, 9 and 12 months. RESULTS: The surgical procedure was considered easy to perform and no post-surgery complication was reported except for one retention. The median number of pads per day decreased significantly from 2 pads before surgery (95% CI: 2 - 3) to 1 during the follow-up period (95% CI: 0 - 2 at 360 days), and at 3 months patients using none or one pad per day were 30% and 32% respectively. The SF 36 continence and quality of life score improved from a median of 100 (95% CI: 83 - 133) to 300 (95% CI: 167 - 375), and the median ICIQ incontinence and quality of life score decreased from 15 (95% CI: 14 - 16) to 8 (95% CI: 5 - 12) one year after surgery. CONCLUSION: The transobturator perineal male sling TOMS is an attractive simple sling technique for moderate or minor post-prostatectomy stress incontinence and offers an improvement in the quality of life.


Asunto(s)
Prostatectomía/efectos adversos , Cabestrillo Suburetral , Incontinencia Urinaria de Esfuerzo/cirugía , Anciano , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Resultado del Tratamiento , Incontinencia Urinaria de Esfuerzo/etiología
13.
Urology ; 129: 43-47, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-30926380

RESUMEN

OBJECTIVE: To evaluate the clinical efficacy, urodynamic effect and safety of Botulinum Toxin A (BTXA) injections after failure of augmentation enterocystoplasty (AE) performed for neurogenic detrusor overactivity. PATIENTS AND METHODS: We performed a multicenter retrospective study that included patients who had AE and at least one injection of BTXA after AE in 15 GENULF (French Speaking Neuro-Urology Study Group) centers. Clinical and urodynamic data were collected from medical files according to a standardized questionnaire and colligated in an anonymous database. RESULTS: Thirty-three patients with an injection of BTXA after AC in 9 out of 15 centers were included. Mean age at the time of AE was 24 ± 15 years. Overall efficacy (defined by clinical efficacy associated with a request by the patient for reinjection) was observed in 58% of the patients. Mean maximum cystomanometric capacity increased by 28% (333 ± 145 vs 426 ± 131 mL; P = .007) and maximum detrusor pressure (Pdet max) decreased by 43% (44 ± 37 vs 25 ± 18 cm H2O; P = .02) after BTXA. Only one side effect was recorded out of the 152 procedures (transient generalized muscle weakness without respiratory distress). CONCLUSION: In patients with failure after AE performed for neurogenic detrusor overactivity, injection of BTXA in the enlarged bladder was effective in over half of the cases with low morbidity. If this therapeutic approach were confirmed, it could be proposed as an alternative to AE surgical revision.


Asunto(s)
Toxinas Botulínicas Tipo A/administración & dosificación , Fármacos Neuromusculares/administración & dosificación , Vejiga Urinaria Neurogénica/tratamiento farmacológico , Vejiga Urinaria Neurogénica/cirugía , Vejiga Urinaria Hiperactiva/tratamiento farmacológico , Vejiga Urinaria Hiperactiva/cirugía , Adolescente , Adulto , Femenino , Humanos , Inyecciones , Masculino , Estudios Retrospectivos , Terapia Recuperativa , Insuficiencia del Tratamiento , Vejiga Urinaria/cirugía , Procedimientos Quirúrgicos Urológicos , Adulto Joven
14.
Int J Gynaecol Obstet ; 102(2): 105-9, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18420207

RESUMEN

OBJECTIVE: To assess the impact of the tension-free vaginal tape (TVT) procedure on the sexual function of women who underwent this treatment for stress urinary incontinence (SUI). METHOD: The Lemack questionnaire was mailed to 135 women treated for SUI only, with no concomitant pelvic organ prolapse repair. RESULTS: Of the 82 returned questionnaires (60.7%), 66 (80.5%) could be included in the analysis. Compared with preoperative responses, there were no significant postoperative changes regarding frequency of sexual intercourse, satisfaction with sexual intercourse, or personal importance of having an active sexual life. Although there was a significant postsurgical decrease in urinary coital incontinence (P=0.02) and 12 women (25.5%) reported improved satisfaction from intercourse, 11 women (23.4%) complained of a worsening. CONCLUSION: These results suggest that TVT for SUI does not significantly affect sexual function in women. Additional prospective studies are warranted to verify these preliminary findings and compare the impact of the TVT with that of other anti-incontinence procedures.


Asunto(s)
Conducta Sexual , Cabestrillo Suburetral , Incontinencia Urinaria de Esfuerzo/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Coito/fisiología , Femenino , Humanos , Persona de Mediana Edad , Satisfacción del Paciente , Periodo Posoperatorio , Estudios Retrospectivos , Conducta Sexual/estadística & datos numéricos
15.
Prog Urol ; 17(5): 917-9, 2007 Sep.
Artículo en Francés | MEDLINE | ID: mdl-17969788

RESUMEN

Multiple medical terms are used in the french medical literature to caracterize an urgency. However, it is a corner stone symptom of bladder overactivity, different from a normal physiological sensation. Specific tools have been designed to measure urgency but there is an essential need to give a specific and clear medical word according to other medical terms for urinary signs or symptoms. This leads to propose urgenturia as the specific medical term for urgency.


Asunto(s)
Enfermedades de la Vejiga Urinaria/clasificación , Vejiga Urinaria Hiperactiva/fisiopatología , Incontinencia Urinaria/etiología , Trastornos Urinarios/fisiopatología , Humanos , Educación del Paciente como Asunto , Enfermedades de la Vejiga Urinaria/fisiopatología , Trastornos Urinarios/clasificación
16.
Prog Urol ; 17(4): 796-800, 2007 Jun.
Artículo en Francés | MEDLINE | ID: mdl-17633989

RESUMEN

Botulinum toxin was first used in urology in the field of neuro-urology as treatment for detrusor-sphincter dyssynergia and incontinence due to neurogenic overactive bladder. Its action has now been clearly demonstrated and it is now widely used for the treatment of neurogenic overactive bladder. Can botulinum toxin also constitute an effective treatment for benign prostatic hyperplasia (BPH)? Intraprostatic botulinum toxin injections have been shown to have a significant clinical and urodynamic efficacy by acting on both the static and dynamic components of BPH. The advantages of botulinum toxin are its ease of use, the absence of any reported adverse effects and its prolonged duration of action. Well conducted, prospective, controlled studies on larger sample sizes must now be performed to confirm these preliminary results. This review of the literature presents the preliminary results of intraprostatic botulinum toxin injection supporting its use in the treatment of symptomatic benign prostatic hyperplasia.


Asunto(s)
Toxinas Botulínicas/uso terapéutico , Hiperplasia Prostática/tratamiento farmacológico , Humanos , Masculino
17.
Prog Urol ; 17(2): 219-24, 2007 Apr.
Artículo en Francés | MEDLINE | ID: mdl-17489322

RESUMEN

AIMS: To assess efficacy of Mémotherm BARD ureteral metallic stent in the treatment of non-operable ureteral stenoses. MATERIAL AND METHOD: Prospective evaluation of ureteral stenoses consecutively treated using Mémotherm BARD ureteral metallic stent. Assessment criteria (recurrence frequency, permeability, tolerance, complications) were measured by clinical examination, Intra Veinous Pyelography, renal sonography, urine culture at 1, and every 3 months. RESULTS: Thirteen stents were inserted in 12 patients (mean age: 68 yrs) presenting with subsequent ureteral stenosis (9 neoplastic, 3 following radiotherapy) over a 3 year period. No technical difficulty was observed. Mean follow-up was 19 months. Stenosis recurrence was observed in 5 patients, due to tumoural progression, but with no tumour in-growth. There was non incrustation or migration, pain, hematuria, infection due to the stent. All stent remained permeable and functional in surviving patients. CONCLUSIONS: In our experience, Mémotherm BARD ureteral metallic stent could be considered a useful cost-effective alternative to double J stent or traditional surgery in non-operable or end-of-life patients. The high ureteral stenosis recurrence rate was linked to the patient initial pathology. Considering these encouraging results, this study could represent the first stage of a multicenter tracker-study, which would permit to take into account further technological development of this type of material.


Asunto(s)
Stents , Enfermedades Ureterales/terapia , Anciano , Anciano de 80 o más Años , Constricción Patológica/etiología , Constricción Patológica/terapia , Progresión de la Enfermedad , Diseño de Equipo , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Permeabilidad , Estudios Prospectivos , Radiografía , Recurrencia , Stents/efectos adversos , Stents/clasificación , Mallas Quirúrgicas , Resultado del Tratamiento , Ultrasonografía , Uréter/diagnóstico por imagen , Uréter/efectos de la radiación , Enfermedades Ureterales/etiología , Neoplasias Ureterales/complicaciones , Neoplasias Ureterales/radioterapia
18.
Prog Urol ; 17(2): 199-202, 2007 Apr.
Artículo en Francés | MEDLINE | ID: mdl-17489318

RESUMEN

INTRODUCTION: Information on prostate diseases, including prostate cancer, has been promoted by the Association Française d'Urologie (AFU) for several years, but is developing slowly in France. In 2005, a first communication was targeted to the male public and identified the reasons for the fatalistic attitude of men, and paradoxically, why the prostate incarnates the vulnerability of their sexual capital. As part of a second phase, this article presents the results of a complementary study conducted among general practitioners to identify their expectations and the most appropriate levers to promote screening. MATERIAL AND METHOD: The Ipsos survey company developed a Krisis qualitative protocol in October 2005 (after the first French prostate day on 15 September 2005). Three groups of general practitioners were defined: doctors who are very active in terms of screening, doctors who are uncomfortable with this problem and doctors who systematically refer their patients to urologists. RESULTS: The management of prostate diseases often highlights the ageing process for the patient. The ability to discuss these problems during the consultation depended on the doctor's degree of comfort with this subject, which is related to his/her training and relationships with urologists. To initiate the question of screening, general practitioners involved in this process asked simple questions about everyday practices without being afraid of making jokes or basing their approach on mediatization of the disease. Digital rectal examination is one of the important clinical elements but is not always easy to perform. PSA was found to be an examination that is not always appropriate, characterized by a lack of information on the conditions for ordering this test, its usefulness and its relevance for screening. Ultrasound could be a way of alerting the patient without dramatizing the situation, letting the urologist perform digital rectal examination. Female general practitioners preferred PSA and ultrasound. The doctors surveyed relied on mediatization of prostate diseases, a high level of interactivity with urologists and documents and brochures to be placed in waiting rooms to relay screening messages. CONCLUSION: General practitioners need their authorities, specialists and public health institutions to develop and mediatize andrology in the same way as gynaecology. Urologists play a major supportive role by means of conferences, postgraduate training or AFU invitations.


Asunto(s)
Tamizaje Masivo , Enfermedades de la Próstata/diagnóstico , Neoplasias de la Próstata/diagnóstico , Envejecimiento/fisiología , Actitud del Personal de Salud , Actitud Frente a la Salud , Comunicación , Tacto Rectal , Medicina Familiar y Comunitaria/educación , Femenino , Francia , Educación en Salud , Promoción de la Salud , Humanos , Relaciones Interprofesionales , Masculino , Educación del Paciente como Asunto , Relaciones Médico-Paciente , Antígeno Prostático Específico/análisis , Enfermedades de la Próstata/diagnóstico por imagen , Neoplasias de la Próstata/diagnóstico por imagen , Salud Pública , Derivación y Consulta , Ultrasonografía , Urología
20.
Prog Urol ; 16(2): 155-9, 2006 Apr.
Artículo en Francés | MEDLINE | ID: mdl-16734237

RESUMEN

OBJECTIVE: To analyse the efficacy of two types of analgesia protocols during outpatient electromagnetic extracorporeal lithotripsy (ESWL) with a STORZ Modulith SLX second generation lithotriptor. MATERIAL AND METHODS: One hundred and seventy one patients were prospectively randomized to 2 groups. Group 1 (n-82) received 40 mg of Piroxicam IM, and group 2 (n=89) received 100 mg Tramadol IV Lithotripsy was performed in 2 sequences, T1 and T2, during which quantitative evaluation of pain (VE) was performed according to a VAS scale and qualitative evaluation of pain (QE) was performed according to the McGill questionnaire. Endpoints included the mean VE and QE pain scores at T1 and T2, the maximum power tolerated at T2, the postoperative pain at the 6th, 12th and 24th hours after ESWL, the pain score according to the power and according to the frequency and adverse effects. Comparisons were performed by analyses of variance (significant for p < 0.05). RESULTS: No significant difference was observed between the two groups for stone dimensions, duration and number of ESWL shots (p > 0.05) and significant difference was observedfor pain with the two drugs used. Pain was more severe as frequency and power increased. Only one intervention was stopped because of pain. Data analysis suggests that tramadol induces more adverse effects. CONCLUSION: Piroxicam and tramadol are two analgesics commonly used in clinical practice and both are suitable for the treatment of pain during outpatient extracorporeal lithotripsy.


Asunto(s)
Analgesia , Analgésicos Opioides/uso terapéutico , Cálculos Renales/terapia , Litotricia/efectos adversos , Dolor/prevención & control , Piroxicam/uso terapéutico , Tramadol/uso terapéutico , Cálculos Ureterales/terapia , Atención Ambulatoria , Femenino , Humanos , Masculino , Persona de Mediana Edad , Dolor/etiología , Estudios Prospectivos , Método Simple Ciego
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA